Sheet	l of	2

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION JUL 2 1 2005 E July 19, 2005 See several sheets if necessary)	ATTORNEY DOCKET NO. 0838.2003-001	NO. APPLICATION NO. 10/601,184		
	FIRST NAMED INVENTOR Garner T. Haupert, Jr.		FILING DATE June 20, 20	03
	EXAMINER Not yet assigned	CONF. 6779	IRMATION NO.	GROUP 1644

	U.S. M. M.	F	OREIGN PATENT D	DCUMENTS		
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSI YES	ATION NO
131	AO2	WO 01/03687 A2	01-18-2001	Cedars-Sinai Medical Center		1
	<u> </u>					
			···			
	ļ					
	<u> </u>					
	-					
	ļ		<u> </u>			
	ļ		···			

ı			 $\overline{}$				
I	EXAMINER	<u></u>	Q	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	DATE CONSIDERED	12/14/06	
۰							

PTO-1449 REPRODUCED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

July 19, 2005

(Use several sheets if necessary)

ATTORNEY	DOCKET	NO.
0838.200	3-001	

application no. 10/601,184

FIRST NAMED INVENTOR Garner T. Haupert, Jr.

FILING DATE June 20, 2003

EXAMINER

Not yet assigned

CONFIRMATION NO. 6779

GROUP 1644

	,	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
nB3	AW4	Qazzaz, H.M.A.M., et al., "Secretion of Lactone-Hydrogenated Ouabain-Like Effector of Sodium, Potassium-Adenosine Triphosphatase Activity by Adrenal Cells," <i>Endrocrinology</i> , 141(9): 3200-3209 (2000).
	·	
	- 1	

		 	
EXAMINER	V_	DATE CONSIDERED	12/14/06

PTO-1449 REPRODUCED O PRODUMATION DISCLOSURE CITATION	ATTORNEY DOCKET NO. 0838.2003-001	APPLICATION NO. 10/601,184			
IN AN APPLICATION December 20, 2004	APPLICANT Garner T. Haupert, Jr., et al.				
BANEWARE (Use several sheets if necessary)	FILING DATE June 20, 2003	CONFIRMATION NO. 6779	GROUP 1644		

		U.	S. PATENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
nD>	AA	6,265,383 B1	July 24, 2001	Haupert, Jr.
j	AB	6,274,558 B1	August 14, 2001	Haupert, Jr.
	AC	5,716,937	February 10, 1998	Haupert, Jr.
	AD	5,910,484	June 8, 1999	Haupert, Jr.
	AE	US 2004 - 0248080 A1	December 9, 2004	Haupert, Jr.
	AF	5,844,091	December 1, 1998	Blaustein, et al.
	AG	5,695,756	December 9, 1997	Blaustein, et al.
1	АН	5,164,296	November 17, 1992	Blaustein, et al.
	AI	•		
	AI	·		·
	AK			
	AA2			
	AB2			
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	A12	¥ .		
	AJ2			
	AK2			
	AA3			
	AB3			
* 1	AC3		7.5	

DWINTER			· · · · · · · · · · · · · · · · · · ·		
EXAMINER	. 🔨	\sim	DATE CONSIDERED	1	
				12/14/06	
	V				J

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

December 20, 2004

(Use several sheets if necessary)

ATTORNEY	DOCKET NO.
0838:200	3-001

APPLICATION NO. 10/601,184

APPLICANT

Garner T. Haupert, Jr., et al.

FILING DATE
June 20, 2003

CONFIRMATION NO. 6779

GROUP 1644

			FOREIGN PATENT	DOCUMENTS		
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANS YES	SLATION NO
13	AL	WO 98/53832 A1	12/03/1998	The General Hospital Corporation		
	AM	WO 98/54195 A1	12/03/1998	The General Hospital Corporation, et al.		
	AN	WO 98/07739 A1	02/26/1998	The General Hospital Corporation, et al.		
	AO	WO 98/53831 A1	12/03/1998	The General Hospital Corporation		
	AP	WO 00/39328 A1	07/06/2000	The General Hospital Corporation		
	AQ	WO 01/25281 A1	04/12/2001	The General Hospital Corporation		
	AL2	WO 2004/000328 A1	12/31/2003	The General Hospital Corporation, et al.		
	AM2	EP 0 983 071 B1	03/08/2000	The General Hospital Corporation		
	AN2	EP 0 433 074 B1	06/19/1991	The General Hospital Corporation		
	AO2					
	AP2					
	AQ2					
	AL3					
	АМЗ					
	AN3					
	AO3					
	AP3					
	AQ3					-
	AL4					
	AM4					
	AN4					
	A04					
	AP4		•			
		<u> </u>				
	AQ4	<u> </u>				

DATE CONSIDERED 12/14/06	
--------------------------	--

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0838.2003-001	APPLICATION NO. 10/601,184	Silect 9 Of .
INFORMATION DISCLOSURE CITATION IN AN APPLICATION December 20, 2004	APPLICANT Garner T. Haupert, Jr., et al.		
(Use several sheets if necessary)	FILING DATE June 20, 2003	CONFIRMATION NO. 6779	GROUP 1644

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
135	AR	Bennett, R.D., et al., "Progesterone Metabolism in Digitalis Lanata", Phytochemistry 7: 41-50 (1968).
	AS	Blaustein, M. P., "Sodium Ions, Calcium Ions, Blood Pressure Regulation, and Hypertension: A Reassessment and a Hypothesis", Am. J. Physiol., 232(5): C165-C173 (1977).
	AT	Blaustein, M.P., "Endogenous Ouabain: Role in the Pathogenesis of Hypertension", Kidney Int. 49(6): 1748-1753 (1996).
	AU	Cantiello, et al., "Na ⁺ Pump in Renal Tubular Cells is Regulated by Endogenous Na ⁺ , K ⁺ - ATPase Inhibitor from Hypothalamus", Am. J. Physiol., 255: F574-580 (1988).
	· AV .	Capsi, E. and Lewis, D.O., "Progesterone: Its Possible Role in the Biosynthesis of Cardenolides in Digitalis Lanata", Science 156(3774): 519-520 (1967).
	AW	Carilli, C. T., et al., "Hypothalamic Factor Inhibits the (Na,K) ATPase from the Extracellular Surface", The Journal of Biological Chemistry, 260(2): 1027-1031 (1985).
	AX	Crabos, M, et al., "Atrial Natriuretic Peptide Regulates Release of Na+-K+-ATPase Inhibitor from Rat Brain", Am. J. Physiol., 254(6): F912-F917 (1988).
	AY	DeAngelis, C. and Haupert, Jr., G. T., "Hypoxia Triggers Release of an Endogenous Inhibitor of Na+, -K+-ATPase from Midbrain and Adrenal", Am. J. Physiol., 274(1): F182-F188 (1998).
	AZ	Ferrandi, M., et al., "Age-Dependency and Dietary Influence on the Hypothalamic Ouabain-Like Factor in Milan Hypertensive Rats", Journal of Hypertension, 13(12): 1571-1574 (1995).
	AR2	Ferrandi, M. and Bianchi, G., "Genetic Mechanisms Underlying the Regulation of Urinary Sodium Excretion and Arterial Blood Pressure: The Role of Adducin", Acta. Physiol. Scand. 168: 187-193 (2000)
	AS2	Ferrandi, M. and Manuta, P., "Ouabain-Like Factor: Is it the Natriuretic Hormone?", Curr. Opin. Nephrol. Hypertens. 9(2): 165-171 (2000).
	AT2	Ferrandi, M., et al., "Ouabain-Like Factor Quantification in Mammalian Tissues and Plasma: Comparison of Two Independent Assays", <i>Hypertension</i> 30(4): 886-896 (1997).
	AU2	Goto, A., et al., "Physiology and Pharmacology of Endogenous Digitalis-Like Factors", Pharmacological Reviews, 44(3): 377-399 (1992).

EXAMINER	DATE CONSIDERED
	(19/01

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION	ATTORNEY DOCKET NO. 0838.2003-001	APPLICATION NO. 10/601,184	
IN AN APPLICATION December 20, 2004	APPLICANT Garner T. Haupert, Jr., et al		
(Use several sheets if necessary)	FILING DATE June 20, 2003	CONFIRMATION NO. 6779	GROUP 1644

	,	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
(3)	AV2	Haber, E. and Haupert, Jr., G. T., "The Search for a Hypothalamic NA+, K+-ATPase Inhibitor", Hypertension, 9(4): 315-324 (1987).
	AW2	Haddy, F. J. and Overbeck, H. W., "The Role of Humoral Agents in Volume Expanded Hypertension", Life Sciences, 19(7): 935-948 (1976).
	AX2	Hallaq, H.A. and Haupert, G.T., Jr., "Positive Inotropic Effects of the Endogenous Na ⁺ /K ⁺ - Transporting ATPase Inhibitor from the Hypothalamus", <i>Proc. Natl. Acad. Sci. USA</i> , 86(24): 10080-10084 (1989).
	AY2	Haupert, Jr., G. and Sancho, J. M., "Sodium Transport Inhibitor from Bovine Hypothalamus", <i>Proc. Natl. Acad. Sci.</i> , 76(9): 4658-4660 (1979).
	AZ2	Haupert, Jr., G. T., et al., "Hypothalamic Sodium-Transport Inhibitor is a High-Affinity Reversible Inhibitor of Na*-K*-ATPase", American Journal of Physiology, 247(6): F919-924 (1984).
	AR3	Janssens, S. P., et al., "Hypothalamic Na ⁺ , K ⁺ -ATPase Inhibitor Constricts Pulmonary Arteries of Spontaneously Hypertensive Rats", Journal of Cardiovascular Pharmacology, 22(Suppl. 2): S42-S46 (1993).
	AS3	Kawamura, A., et al., "On the Structure of Endogenous Ouabain", Proc. Natl. Acad. Sci., 96: 6654-6659 (1999).
	АТ3	Kitano, S., et al., "Exogenous Ouabain is Accumulated in the Adrenals and Mimics the Kinetics of Endogenous Digitalis-Like Factor in Rats", Hypertens Res, 21(1): 47-56 (1998).
	AU3	Komiyama, Y., et al., "Identification of Endogenous Ouabain in Culture Supernatant of PC12 Cells", Journal of Hyppertension, 19(2): 229-236 (2001).
	AV3	Laredo, J., et al., "Angiotensin II Stimulates Secretion of Endogenous Ouabain from Bovine Adrenocortical Cells via Angiotensin Type 2 Receptors", Hypertension, 29(1): 401-407 (1997).
	AW3	Lichtstein, D., et al., "Biosynthesis of Digitalis-Like Compounds in Rat Adrenal Cells: Hydroxycholesterol as Possible Precursor", Life Sciences, 62(23): 2109-2126 (1998).
L	AX3	Lu, Z., et al., "Biosynthesis of Endogenous Ouabain from Pregnenolone and Progesterone in Bovine Adrenal Cortical Cells", Hypertension, 32(3): 624 (1998).

DATE CONSIDERED WILLIAM WILLIAM	 · .
ORED 1. VO	17-1141-1

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0838.2003-001	APPLICATION NO. 10/601,184	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION December 20, 2004	APPLICANT Garner T. Haupert, Jr.	, et al.	
(Use several sheets if necessary)	FILING DATE June 20, 2003	CONFIRMATION NO. 6779	GROUP 1644

			OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
hy.	5	AY3	Orth, D. N. and Kovacs, W. J., "The Adrenal Cortex". In Williams Textbook of Endocrinology 9th Edition, Jean. D. Wilson, M.D., et al., eds. (W. B. Saunders Company), pp. 517-664 (1998).
		AZ3	Perrin, A., et al., "Bovine Adrenocortical Cells in Culture Synthesize an Ouabain-Like Compound", Molecular and Cellular Endocrinology, 126: 7-15 (1997).
		AR4	Quazzaz, H. M. A. M., et al., "Deglycosylated Products of Endogenous Digoxin-Like Immunoreactive Factor in Mammalian Tissue", <i>The Journal of Biological Chemistry</i> , 271(15): 8731-8737 (1996).
		AS4	Robel, P. and Baulier, E., "Neurosteroids: Biosynthesis and Function", Neurobiolgy, 9(4): 383-394 (1995).
		AT4	Tamura, M., et al., "Identification of Two Cardiac Glycosides as Na ⁺ - Pump Inhibitors in Rat Urine and Diet", The Journal of Biological Chemistry, 269(16): 11972-11979 (1994).
		AU4	Tymiak, A. A., et al., "Physicochemical Characterization of a Ouabain Isomer Isolated from Bovine Hypothalamus", Proc. Natl. Acad. Sci., 90: 8189-8193 (1993).
		AV4	Elbashir, S.M., et al., "Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells," Nature, 411: 494-498 (2001).
	_		
	-		

EXAMINER	DATE CONSIDERED
	12/11/1
	ν

[X] Applicant requests that the following non-published pending applications be considered:

Examiner's Initials	5
(20)	U.S. Patent Application No. 09/220,913, by Garner T. Haupert, Jr., filed December 24, 1998, Atty. Docket No.: 0838.1002-000
13/	U.S. Patent Application No. 09/412,268, by Behnaz Parharmi-Seren, et al., filed October 5, 1999, Atty. Docket No.: 0838.1004-000
(h)	U.S. Patent Application No. 09/506,246, by Rex T. Gallagher, et al., filed February 17, 2000, Atty. Docket No.: 2075.1002-003
	Examiner Date
	Date
•	[X] A copy of each above-cited application, including the current claims, is enclosed.
	[] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.
The Ex	xaminer is requested to return a copy of the above list of pending applications indicating which nees were considered with the next office communication.
	quested that the information disclosed herein be made of record in this application.
Metho	d of payment:
[]	A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
[]	Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
[X]	Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.
	Respectfully submitted,
	HAMILTON, BROOK, SMITH & REYNOLDS, P.C.
	By from the
	Kraig K. Anderson Registration No.: 54.961
	Registration No.: 54,961 Telephone: (978) 341-0036 Facsimile: (978) 341-0136
Concor	rd, MA 01742-9133
Dated:	1 peulon 20, 2004